External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EAHAD 2024

-
Coming soon
01:00 PM
Duration 75mins Frankfurt, Germany
The right time to start – what is the evidence for early prophylaxis in haemophilia A?
Dr Carmen Escuriola-Ettingshausen, Julia Spires,Teresa Pereira, Dr Gili Kenet

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:30 PM
Duration 1hr Frankfurt, Germany
Emicizumab in People with Moderate or Mild Haemophilia A Aged ≥40 Years, with and without Comorbidities
Jimenez-Yuste V, Tzeng E, Lim E, Ventriglia G, Shapiro A, Oldenburg J, Mahlangu J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Frankfurt, Germany
Emicizumab Prophylaxis in People with Haemophilia A: Summary of 10 Years of Safety Data on Thromboembolic Events and Thrombotic Microangiopathy
Sarouei K, Barlera S, Polito L, Tobaruela G, Biondo J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:33 AM
Duration 9mins Panorama 1, 2, 3
Emicizumab Prophylaxis in Infants with Severe Haemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study
Pipe S, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jimenez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Chang T, Lehle M, Niggli M, Fijnvandraat K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar